New data showed that Roche’s Tecentriq could help some lung cancer patients live longer. But what they didn’t show may be just as important.
After batting aside efficacy questions in head and neck cancer, Merck’s Keytruda is back with a new batch of data, this time in new patients.
BMS is looking to push its Opdivo-Yervoy combo further into colorectal cancer, and with new phase 2 data, it just might be able to.
Pfizer has long been kidney cancer player, but it’s looking to take things up a notch with its latest immunotherapy data.
AZ and Merck's Lynparza has posted data in BRCA-mutated patients who've just wrapped up an initial round of chemo. And it’s entering with a bang.
Pfizer’s Ibrance failed to prove it could help some patients live longer, but executives say those study results still make a “compelling” case.
Roche’s Tecentriq is gunning for a first-in-class triple-negative breast cancer nod, and it’s out with data that could help it get the job done.
Earlier this month, Clovis' Rubraca won the FDA’s breakthrough tag in prostate cancer. Now, Clovis has unveiled the data that got it the distinction.
Shire just nabbed FDA panel backing for prucalopride, aiming to challenge Allergan and Synergy in the chronic constipation market.
As a big ESMO 2018 kicks off, here are the studies we're most excited to see.
